Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

News

 

Bain Capital eyes controlling stake in India’s HCG from CVC Capital

Bain Capital, the American private investment firm, is the leading candidate to acquire a 60.4% controlling stake in India-based cancer care provider HealthCare Global Enterprises (HCG), from CVC Capital Partners, a Luxembourg-based private equity and investment advisory firm, CNBCTV18 reported. The stake is said to have been valued at approximately $356 million, while HCG’s market value stands at $589 million despite a 3% drop in its share price this year. Negotiations are ongoing, and the deal is not yet finalised. 

Germany’s pharmaceutical company STADA expands its presence in MENA region

STADA, a European pharmaceutical company based in Germany, has acquired the FITO™ trademark from Leo Pharma, a multinational Danish pharmaceutical company, to expand its consumer healthcare presence in the Middle East and North Africa (MENA) region.  International law firm Bird & Bird has advised STADA Group on acquiring the FITO business from Leo Pharma in an asset deal.

PE firm Quadria Capital to invest approximately $1 billion in Indian healthcare market

Asia's largest healthcare-focused PE firm Quadria Capital is going to invest approximately $1 billion into various healthcare companies in India’s healthcare sector in the next two and  a half years. The investment will be made into hospitals, pharmaceuticals, life sciences and medical devices. Sunil Thakur, Partner and Head of South Asia at Quadria Capital said […]

HBI News Round Up, Friday 16th August 2024

In this HBI News Round Up we cover Bupa Health Services’ acquisition of diabetes specialist outpatient clinic, London Medical, Optegra Eye Health Care’s opening of a new NHS cataract clinic in West London, healthcare operations software provider, Agilio’s acquisition of specialist pharmacy e-learning business, Mediapharm, US-owned mental health and addiction therapy provider All Points North […]

How CRISPR and HiBiT can accelerate drug discovery

CRISPR has been called one of the most exciting developments in genetic engineering. It is opening up new possibilities in medicine, particularly for discovering new types of drugs for genetic diseases and new ways of repairing and replacing organs and tissue in regenerative medicine. In an interview with HBI, Philip Hargreaves, Director of Strategic Marketing & Business Development at Promega UK, the UK  branch of US biotech company Promega, spoke about how CRISPR, when combined with Promega’s innovative HiBiT technology, can accelerate the drug discovery process.

Find Us